Glucosylceramidase
-
Subject Areas on Research
- A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
- Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression.
- Divergent phenotypes in Gaucher disease implicate the role of modifiers.
- Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.
- Factors that influence the uptake and turnover of glucocerebrosidase and alpha-galactosidase in mammalian liver.
- Gaucher disease. Current issues in diagnosis and treatment. NIH Technology Assessment Panel on Gaucher Disease.
- Glucocerebrosidase gene mutations associated with Parkinson's disease: a meta-analysis in a Chinese population.
- L-glucosylceramide: synthesis, properties, and resistance to catabolism by glucocerebrosidase in vitro.
- Rapid assays for Gaucher and Hurler diseases in dried blood spots using digital microfluidics.
- Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India.
- Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
- Tumor-induced reshuffling of lipid composition on the endoplasmic reticulum membrane sustains macrophage survival and pro-tumorigenic activity.
- Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.